Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT02195895·Phase 2·INTERVENTIONAL

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

TeriparatideOtherCompleted

Status

Completed

Phase

Phase 2

Enrollment

17

Locations

1

Results

Posted

Publications

0

Study summary

What the protocol is testing.

The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI). This study will also investigate 1) if alendronate therapy will increase bone strength in people with chronic SCI, 2) the number of participants with adverse events from alendronate, and 3) the effects of alendronate on serum markers of bone metabolism.

Full detailed description

This extension study will enroll individuals who have completed treatment in the parent protocol "Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury" or in the teriparatide extension protocol. This study will allow those individuals who previously received teriparatide to be treated for a year with alendronate to maintain any bone they may have gained and to possibly increase bone mass further. Termination of teriparatide is followed by bone loss if anti-resorptive therapy is not initiated, so this approach is optimal for continued treatment of the current group of participants.

Interventions

Treatment arms and agents.

DRUG

Alendronate

Weekly oral alendronate 70 mg for 12 months

DIETARY_SUPPLEMENT

Calcium

Daily oral 1000 mg Calcium

DIETARY_SUPPLEMENT

Vitamin D

Daily oral 1000 IU

Timeline

From registration to results.

  1. First posted

    Jul 21, 2014

  2. Study start

    Apr 2014

  3. Primary completion

    Aug 5, 2016

  4. Study completion

    Aug 5, 2016

  5. Results posted

    Sep 26, 2018

  6. Registry updated

    Mar 30, 2023

Outcomes

What the study measures.

Primary outcomes

BMD of Total Hip by DXA

Time frame · 12 months

The mean percent change in bone mineral density (BMD) of the hip after 12 months of treatment. BMD was evaluated by dual-energy X-ray absorptiometry (DXA). DXA scans measure bone density in different areas of the body using low-dose X-ray beams.

Secondary outcomes

C-terminal Telopeptide (CTX)

Time frame · 12 months

The mean percent change in C-terminal telopeptide (CTX) from baseline after 12 months of treatment. CTX is a bone marker found in blood serum and measures the rate of bone breakdown.

BMD by DXA at the Lumbar Spine

Time frame · 12 months

The mean percent change in bone mineral density (BMD) in the lumbar spine after 12 months of treatment. BMD was evaluated by dual-energy X-ray absorptiometry (DXA). DXA scans measure bone density in different areas of the body using low-dose X-ray beams.

Amino-terminal Propeptide of Type 1 Collagen (P1NP)

Time frame · 12 months

The mean percent change in amino-terminal of type 1 collagen (P1NP) from baseline after 12 months of treatment. P1NP is a bone marker found in blood serum and provides information about how fast the body is making new bone.

Bone-specific Alkaline Phosphatase (BSAP)

Time frame · 12 months

The mean percent change in bone-specific alkaline phosphatase (BSAP) after 12 months of treatment. BSAP is a bone marker found in blood serum and measures the rate of bone breakdown.

Eligibility

Who can take part.

Minimum age
21 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Prior enrollment in protocol "Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury", (NCT01225055). * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Individual with renal insufficiency (calculated creatinine clearance \< 30 ml/min). * Individuals who are not able to sit or stand upright for at least 30 minutes after taking their medication. * Individuals with poor dental hygiene. * Individuals with esophageal abnormalities. * Individuals who are not able to tolerate alendronate treatment. * Individuals who will not be able to return for all study visits. * Patients may not be receiving any other investigational agents. * Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Teriparatide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsTeriparatide trial dashboard →DatabaseTeriparatide database entry →ResearchTeriparatide research guide →